权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Biomedical Engineering Core

生物医学工程核心

基本信息

批准号：
10115111
负责人：
Steven Allan Soper
金额：
$ 23.89万
依托单位：
UNIVERSITY OF KANSAS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-02-15 至 2024-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10115111
关键词：
Address Area Automation Basic Science Biological Biological Assay Biological Markers Biology Biomedical Engineering Biotechnology Blood Cells Centers of Research Excellence Characteristics Clinical Communities Consensus Consumption DNA Data Data Set Development Disease Disease model Educational workshop Faculty Functional disorder Funding Generations Goals Hand Human Resources Immunoassay Infrastructure Injections Institutes Kansas Lab-On-A-Chips Laboratories Liquid substance Malignant Neoplasms Measurement Microfluidics Mission Molds Molecular Mutation Detection National Institute of Biomedical Imaging and Bioengineering Nature Neoplasm Circulating Cells Oncology Patient-Focused Outcomes Patients Performance Plastics Process Production Proteins Proteomics RNA Reagent Research Personnel Resources Saliva Sampling Secure Services Structure System Technology Time Translating Translational Research Treatment Protocols United States National Institutes of Health Urine Validation Work base bioimaging cell free DNA circulating biomarkers clinical translation commercialization cost design exosome extracellular vesicles human disease improved in-vitro diagnostics innovation liquid biopsy liquid chromatography mass spectrometry meetings member minimally invasive nanometer new technology next generation sequencing novel therapeutics precision medicine prototype success tool web site

项目摘要

Abstract Circulating markers found in accessible samples (blood, saliva, urine, etc.) represent an exciting biomarker class due to the minimally invasive nature of securing them. Potentially, these circulating markers can enable studies directed toward understanding the pathophysiology of a disease and translating those discoveries to the bedside for managing a host of human diseases by matching the molecular characteristics of the disease to proper treatment regimens (i.e., precision medicine). The attractive nature of circulating markers (i.e., liquid biopsy markers) is the plethora of marker types found in the sample such as biological cells, cell-free molecules (proteins and cell-free DNA) and extracellular vesicles (nanometer assemblies such as exosomes). Unfortunately, basic studies and clinical translation of these liquid biopsy markers has been challenging due to the lack of efficient platforms for their isolation that can also accommodate downstream molecular characterization of the circulating marker cargo. KIPM will generate the Biomedical Engineering Core that will provide to COBRE investigators transformative tools, including hardware and the associated assays, that can be programmed for the project at hand and provide to investigators high quality circulating markers to serve as inputs for a variety of molecular characterization assays (DNA/RNA Next Generation Sequencing, proteomics, immunoassays, mutation detection, liquid chromatography/mass spectrometry, and many others). The hardware tools are lab-on-a-chip or microfluidic platforms that have been optimized for the isolation of circulating markers and clinically validated in a variety of application areas. The microfluidic tools also have validated assays and an automated workflow that has been developed by members of the BME Core. These tools have noteworthy performance metrics compared to commercially available products directed for the isolation of circulating markers. The microfluidics are produced in a high scale production mode at low cost because they are made from plastics and formed into the appropriate structures using injection molding, an established production pipeline for producing CDs, DVDs and Blu-Ray discs. Using these tool sets, the BME Core will create a laboratory that can immediately service COBRE investigators on their precision medicine based projects. Due to the unique capabilities of the tools employed by the BME Core, the data sets generated by the KIPM investigators and the unique tools to acquire these data sets will improve their competitiveness in seeking federally-funded support of their projects. For COBRE projects that cannot be effectively serviced by the Core’s existing tools, the Core will work with the project PI to design new tools to accommodate their project that will also add new process capabilities to the BME Core. The BME Core has assay design capabilities and prototyping tools to support this activity.

摘要